Splicing: is there an alternative contribution to Parkinson’s disease?
10.1007/s10048-015-0449-x
Crossref journal-article
Springer Science and Business Media LLC
neurogenetics (297)
Bibliography

La Cognata, V., D’Agata, V., Cavalcanti, F., & Cavallaro, S. (2015). Splicing: is there an alternative contribution to Parkinson’s disease? Neurogenetics, 16(4), 245–263.

Authors 4
  1. Valentina La Cognata (first)
  2. Velia D’Agata (additional)
  3. Francesca Cavalcanti (additional)
  4. Sebastiano Cavallaro (additional)
References 137 Referenced 59
  1. Ward AJ, Cooper TA (2010) The pathobiology of splicing. J Pathol 220(2):152–163. doi: 10.1002/path.2649 (10.1002/path.2649) / J Pathol by AJ Ward (2010)
  2. Yap K, Makeyev EV (2013) Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms. Mol Cell Neurosci 56:420–428. doi: 10.1016/j.mcn.2013.01.003 (10.1016/j.mcn.2013.01.003) / Mol Cell Neurosci by K Yap (2013)
  3. Calarco JA, Zhen M, Blencowe BJ (2011) Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts. RNA 17(5):775–791. doi: 10.1261/rna.2603911 (10.1261/rna.2603911) / RNA by JA Calarco (2011)
  4. Li Q, Lee JA, Black DL (2007) Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci 8(11):819–831. doi: 10.1038/nrn2237 (10.1038/nrn2237) / Nat Rev Neurosci by Q Li (2007)
  5. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40(12):1413–1415. doi: 10.1038/ng.259 (10.1038/ng.259) / Nat Genet by Q Pan (2008)
  6. Behzadnia N, Golas MM, Hartmuth K, Sander B, Kastner B, Deckert J, Dube P, Will CL, Urlaub H, Stark H, Luhrmann R (2007) Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. EMBO J 26(6):1737–1748. doi: 10.1038/sj.emboj.7601631 (10.1038/sj.emboj.7601631) / EMBO J by N Behzadnia (2007)
  7. Shefer K, Sperling J, Sperling R (2014) The supraspliceosome—a multi-task machine for regulated pre-mRNA processing in the cell nucleus. Comput Struct Biotechnol J 11(19):113–122. doi: 10.1016/j.csbj.2014.09.008 (10.1016/j.csbj.2014.09.008) / Comput Struct Biotechnol J by K Shefer (2014)
  8. Gamazon ER, Stranger BE (2014) Genomics of alternative splicing: evolution, development and pathophysiology. Hum Genet 133(6):679–687. doi: 10.1007/s00439-013-1411-3 (10.1007/s00439-013-1411-3) / Hum Genet by ER Gamazon (2014)
  9. Scuderi S, La Cognata V, Drago F, Cavallaro S, D’Agata V (2014) Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed Res Int 2014:690796. doi: 10.1155/2014/690796 (10.1155/2014/690796) / Biomed Res Int by S Scuderi (2014)
  10. Licatalosi DD, Darnell RB (2006) Splicing regulation in neurologic disease. Neuron 52(1):93–101. doi: 10.1016/j.neuron.2006.09.017 (10.1016/j.neuron.2006.09.017) / Neuron by DD Licatalosi (2006)
  11. Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta 1792(1):14–26. doi: 10.1016/j.bbadis.2008.09.017 (10.1016/j.bbadis.2008.09.017) / Biochim Biophys Acta by J Tazi (2009)
  12. Singh RK, Cooper TA (2012) Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18(8):472–482. doi: 10.1016/j.molmed.2012.06.006 (10.1016/j.molmed.2012.06.006) / Trends Mol Med by RK Singh (2012)
  13. Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136(4):777–793. doi: 10.1016/j.cell.2009.02.011 (10.1016/j.cell.2009.02.011) / Cell by TA Cooper (2009)
  14. Lewis PA, Cookson MR (2012) Gene expression in the Parkinson’s disease brain. Brain Res Bull 88(4):302–312. doi: 10.1016/j.brainresbull.2011.11.016 (10.1016/j.brainresbull.2011.11.016) / Brain Res Bull by PA Lewis (2012)
  15. Bonifati V (2014) Genetics of Parkinson’s disease—state of the art, 2013. Parkinsonism Relat Disord 20(1):S23–S28. doi: 10.1016/S1353-8020(13)70009-9 (10.1016/S1353-8020(13)70009-9) / Parkinsonism Relat Disord by V Bonifati (2014)
  16. Lubbe S, Morris HR (2014) Recent advances in Parkinson’s disease genetics. J Neurol 261(2):259–266. doi: 10.1007/s00415-013-7003-2 (10.1007/s00415-013-7003-2) / J Neurol by S Lubbe (2014)
  17. Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454. doi: 10.1038/nrneurol.2013.132 (10.1038/nrneurol.2013.132) / Nat Rev Neurol by J Trinh (2013)
  18. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson’s Disease Genomics C, Parkinson’s Study Group Parkinson’s Research: The Organized GI, andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G, Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North American Brain Expression C, United Kingdom Brain Expression C, Greek Parkinson’s Disease C, Alzheimer Genetic Analysis G, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46(9):989–993. doi: 10.1038/ng.3043 (10.1038/ng.3043) / Nat Genet by MA Nalls (2014)
  19. Stefanis L (2012) Alpha-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2(2):a009399. doi: 10.1101/cshperspect.a009399 (10.1101/cshperspect.a009399) / Cold Spring Harb Perspect Med by L Stefanis (2012)
  20. Pihlstrom L, Toft M (2011) Genetic variability in SNCA and Parkinson’s disease. Neurogenetics 12(4):283–293. doi: 10.1007/s10048-011-0292-7 (10.1007/s10048-011-0292-7) / Neurogenetics by L Pihlstrom (2011)
  21. Deng H, Yuan L (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev 15C:161–176. doi: 10.1016/j.arr.2014.04.002 (10.1016/j.arr.2014.04.002) / Ageing Res Rev by H Deng (2014)
  22. Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den Broeck M, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van Broeckhoven C, Theuns J (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061. doi: 10.1002/humu.21007 (10.1002/humu.21007) / Hum Mutat by K Nuytemans (2009)
  23. Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9(1):15–23. doi: 10.1007/s10048-007-0106-0 (10.1007/s10048-007-0106-0) / Neurogenetics by K Beyer (2008)
  24. Beyer K, Domingo-Sabat M, Humbert J, Carrato C, Ferrer I, Ariza A (2008) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9(3):163–172. doi: 10.1007/s10048-008-0124-6 (10.1007/s10048-008-0124-6) / Neurogenetics by K Beyer (2008)
  25. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson’s disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49(2):230–239. doi: 10.1016/j.mcn.2011.11.006 (10.1016/j.mcn.2011.11.006) / Mol Cell Neurosci by JR McLean (2012)
  26. Cardo LF, Coto E, de Mena L, Ribacoba R, Mata IF, Menendez M, Moris G, Alvarez V (2014) Alpha-synuclein transcript isoforms in three different brain regions from Parkinson’s disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci Lett 562:45–49. doi: 10.1016/j.neulet.2014.01.009 (10.1016/j.neulet.2014.01.009) / Neurosci Lett by LF Cardo (2014)
  27. Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 30(6):601–607. doi: 10.1111/j.1365-2990.2004.00572.x (10.1111/j.1365-2990.2004.00572.x) / Neuropathol Appl Neurobiol by K Beyer (2004)
  28. Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, Lopez D, Ferrer I, Ariza A (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 17(12):1327–1330. doi: 10.1097/01.wnr.0000224773.66904.e7 (10.1097/01.wnr.0000224773.66904.e7) / Neuroreport by K Beyer (2006)
  29. McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O (2011) The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 12(1):59–64. doi: 10.1007/s10048-010-0263-4 (10.1007/s10048-010-0263-4) / Neurogenetics by JJ McCarthy (2011)
  30. Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B (2010) Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson’s disease. Free Radic Biol Med 48(3):377–383. doi: 10.1016/j.freeradbiomed.2009.10.045 (10.1016/j.freeradbiomed.2009.10.045) / Free Radic Biol Med by SV Kalivendi (2010)
  31. Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W, Abeliovich A (2012) Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson’s disease pathology. Nat Commun 3:1084. doi: 10.1038/ncomms2032 (10.1038/ncomms2032) / Nat Commun by H Rhinn (2012)
  32. Beyer K (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112(3):237–251. doi: 10.1007/s00401-006-0104-6 (10.1007/s00401-006-0104-6) / Acta Neuropathol by K Beyer (2006)
  33. Bungeroth M, Appenzeller S, Regulin A, Volker W, Lorenzen I, Grotzinger J, Pendziwiat M, Kuhlenbaumer G (2014) Differential aggregation properties of alpha-synuclein isoforms. Neurobiol Aging 35(8):1913–1919. doi: 10.1016/j.neurobiolaging.2014.02.009 (10.1016/j.neurobiolaging.2014.02.009) / Neurobiol Aging by M Bungeroth (2014)
  34. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999):1663–1667. doi: 10.1126/science.1195227 (10.1126/science.1195227) / Science by J Burre (2010)
  35. Rideout HJ, Stefanis L (2014) The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson’s disease. Neurochem Res 39(3):576–592. doi: 10.1007/s11064-013-1073-5 (10.1007/s11064-013-1073-5) / Neurochem Res by HJ Rideout (2014)
  36. Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB (2007) Comprehensive screening of a North American Parkinson’s disease cohort for LRRK2 mutation. Neurodegener Dis 4(5):386–391. doi: 10.1159/000105160 (10.1159/000105160) / Neurodegener Dis by J Johnson (2007)
  37. Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yuen Y, Farrer M, Liu JJ, Tan EK (2005) Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65(8):1319–1321. doi: 10.1212/01.wnl.0000180517.70572.37 (10.1212/01.wnl.0000180517.70572.37) / Neurology by L Skipper (2005)
  38. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65(5):741–744. doi: 10.1212/01.wnl.0000172630.22804.73 (10.1212/01.WNL.0000172630.22804.73) / Neurology by CP Zabetian (2005)
  39. Shojaee S, Sina F, Farboodi N, Fazlali Z, Ghazavi F, Ghorashi SA, Parsa K, Sadeghi H, Shahidi GA, Ronaghi M, Elahi E (2009) A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson’s disease patients. Mov Disord 24(7):1023–1027. doi: 10.1002/mds.22503 (10.1002/mds.22503) / Mov Disord by S Shojaee (2009)
  40. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V, Italian Parkinson’s Genetics N (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet 14(3):322–331. doi: 10.1038/sj.ejhg.5201539 (10.1038/sj.ejhg.5201539) / Eur J Hum Genet by A Fonzo Di (2006)
  41. Grimes DA, Racacho L, Han F, Panisset M, Bulman DE (2007) LRRK2 screening in a Canadian Parkinson’s disease cohort. Can J Neurol Sci 34(3):336–338 (10.1017/S0317167100006788) / Can J Neurol Sci by DA Grimes (2007)
  42. Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB (2008) Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat 29(4):485–490. doi: 10.1002/humu.20668 (10.1002/humu.20668) / Hum Mutat by C Paisan-Ruiz (2008)
  43. Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Pechoux S, Brefel-Courbon C, Destee A, Tranchant C, Romana M, Leclere L, Durr A, Brice A, French Parkinson’s Disease Genetics Study G (2009) Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease. J Med Genet 46(7):458–464. doi: 10.1136/jmg.2008.062612 (10.1136/jmg.2008.062612) / J Med Genet by S Lesage (2009)
  44. Trabzuni D, Ryten M, Emmett W, Ramasamy A, Lackner KJ, Zeller T, Walker R, Smith C, Lewis PA, Mamais A, de Silva R, Vandrovcova J, International Parkinson Disease Genomics C, Hernandez D, Nalls MA, Sharma M, Garnier S, Lesage S, Simon-Sanchez J, Gasser T, Heutink P, Brice A, Singleton A, Cai H, Schadt E, Wood NW, Bandopadhyay R, Weale ME, Hardy J, Plagnol V (2013) Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS ONE 8(8):e70724. doi: 10.1371/journal.pone.0070724 (10.1371/journal.pone.0070724) / PLoS ONE by D Trabzuni (2013)
  45. Giesert F, Hofmann A, Burger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W (2013) Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS ONE 8(5):e63778. doi: 10.1371/journal.pone.0063778 (10.1371/journal.pone.0063778) / PLoS ONE by F Giesert (2013)
  46. Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, Lee CW, Sung WK, Tan EK, Lufkin T, Jesuthasan S, Sinnakaruppan M, Liu J (2010) Deletion of the WD40 domain of LRRK2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect. PLoS Genet 6(4):e1000914. doi: 10.1371/journal.pgen.1000914 (10.1371/journal.pgen.1000914) / PLoS Genet by D Sheng (2010)
  47. Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89(1):162–167. doi: 10.1016/j.ajhg.2011.06.001 (10.1016/j.ajhg.2011.06.001) / Am J Hum Genet by C Vilarino-Guell (2011)
  48. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89(1):168–175. doi: 10.1016/j.ajhg.2011.06.008 (10.1016/j.ajhg.2011.06.008) / Am J Hum Genet by A Zimprich (2011)
  49. Verstraeten A, Wauters E, Crosiers D, Meeus B, Corsmit E, Elinck E, Mattheijssens M, Peeters K, Cras P, Pickut B, Vandenberghe R, Engelborghs S, De Deyn PP, Van Broeckhoven C (1844) Theuns J (2012) Contribution of VPS35 genetic variability to LBD in the Flanders–Belgian population. Neurobiol Aging 33(8):e1811–e1843. doi: 10.1016/j.neurobiolaging.2012.01.006 / Neurobiol Aging by A Verstraeten (1844)
  50. Bonifati V (2012) Autosomal recessive parkinsonism. Parkinsonism Relat Disord 18(1):S4–S6. doi: 10.1016/S1353-8020(11)70004-9 (10.1016/S1353-8020(11)70004-9) / Parkinsonism Relat Disord by V Bonifati (2012)
  51. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A, French Parkinson’s Disease Genetics Study G, European Consortium on Genetic Susceptibility in Parkinson’s D (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342(21):1560–1567. doi: 10.1056/NEJM200005253422103 (10.1056/NEJM200005253422103) / N Engl J Med by CB Lucking (2000)
  52. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM (2003) Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease. Ann Neurol 53(5):624–629. doi: 10.1002/ana.10524 (10.1002/ana.10524) / Ann Neurol by SA Oliveira (2003)
  53. Illarioshkin SN, Periquet M, Rawal N, Lucking CB, Zagorovskaya TB, Slominsky PA, Miloserdova OV, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, Brice A (2003) Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism. Mov Disord 18(8):914–919. doi: 10.1002/mds.10467 (10.1002/mds.10467) / Mov Disord by SN Illarioshkin (2003)
  54. Pigullo S, De Luca A, Barone P, Marchese R, Bellone E, Colosimo A, Scaglione C, Martinelli P, Di Maria E, Pizzuti A, Abbruzzese G, Dallapiccola B, Ajmar F, Mandich P (2004) Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord 10(6):357–362. doi: 10.1016/j.parkreldis.2004.04.012 (10.1016/j.parkreldis.2004.04.012) / Parkinsonism Relat Disord by S Pigullo (2004)
  55. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP (2004) Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127(Pt 6):1332–1342. doi: 10.1093/brain/awh150 (10.1093/brain/awh150) / Brain by C Scherfler (2004)
  56. Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E, Antonini A, Stocchi F, Montagna P, Squitieri F, Marini P, Abbruzzese G, Fabbrini G, Marconi R, Dalla Libera A, Trianni G, Guidi M, De Gaetano A, Boff Maegawa G, De Leo A, Gallai V, de Rosa G, Vanacore N, Meco G, van Duijn CM, Oostra BA, Heutink P, Bonifati V, Italian Parkinson Genetics N (2005) Novel parkin mutations detected in patients with early-onset Parkinson’s disease. Mov Disord 20(4):424–431. doi: 10.1002/mds.20343 (10.1002/mds.20343) / Mov Disord by AM Bertoli-Avella (2005)
  57. Bardien S, Keyser R, Yako Y, Lombard D, Carr J (2009) Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson’s disease. Parkinsonism Relat Disord 15(2):116–121. doi: 10.1016/j.parkreldis.2008.04.005 (10.1016/j.parkreldis.2008.04.005) / Parkinsonism Relat Disord by S Bardien (2009)
  58. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, Parkinson Study Group PI (2009) Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 73(4):279–286. doi: 10.1212/WNL.0b013e3181af7a33 (10.1212/WNL.0b013e3181af7a33) / Neurology by N Pankratz (2009)
  59. La Cognata V, Iemmolo R, D’Agata V, Scuderi S, Drago F, Zappia M, Cavallaro S (2014) Increasing the coding potential of genomes through alternative splicing: the case of PARK2 gene. Curr Genomics 15(3):203–216. doi: 10.2174/1389202915666140426003342 (10.2174/1389202915666140426003342) / Curr Genomics by V Cognata La (2014)
  60. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608 (10.1038/33416) / Nature by T Kitada (1998)
  61. Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y (1997) Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2–27. Am J Hum Genet 60(3):588–596 / Am J Hum Genet by H Matsumine (1997)
  62. Xu L, Lin DC, Yin D, Koeffler HP (2014) An emerging role of PARK2 in cancer. J Mol Med (Berl) 92(1):31–42. doi: 10.1007/s00109-013-1107-0 (10.1007/s00109-013-1107-0) / J Mol Med (Berl) by L Xu (2014)
  63. Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T (2009) Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced parkin in human colorectal cancers. Int J Cancer 125(9):2029–2035. doi: 10.1002/ijc.24565 (10.1002/ijc.24565) / Int J Cancer by K Ikeuchi (2009)
  64. Kitada T, Asakawa S, Minoshima S, Mizuno Y, Shimizu N (2000) Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm Genome 11(6):417–421 (10.1007/s003350010080) / Mamm Genome by T Kitada (2000)
  65. Humbert J, Beyer K, Carrato C, Mate JL, Ferrer I, Ariza A (2007) Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol Dis 26(3):681–687. doi: 10.1016/j.nbd.2007.03.007 (10.1016/j.nbd.2007.03.007) / Neurobiol Dis by J Humbert (2007)
  66. Tan EK, Shen H, Tan JM, Lim KL, Fook-Chong S, Hu WP, Paterson MC, Chandran VR, Yew K, Tan C, Yuen Y, Pavanni R, Wong MC, Puvan K, Zhao Y (2005) Differential expression of splice variant and wild-type parkin in sporadic Parkinson’s disease. Neurogenetics 6(4):179–184. doi: 10.1007/s10048-005-0001-5 (10.1007/s10048-005-0001-5) / Neurogenetics by EK Tan (2005)
  67. Dagata V, Cavallaro S (2004) Parkin transcript variants in rat and human brain. Neurochem Res 29(9):1715–1724 (10.1023/B:NERE.0000035807.25370.5e) / Neurochem Res by V Dagata (2004)
  68. Sunada Y, Saito F, Matsumura K, Shimizu T (1998) Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci Lett 254(3):180–182 (10.1016/S0304-3940(98)00697-1) / Neurosci Lett by Y Sunada (1998)
  69. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr (2000) Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol 47(2):201–210 (10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F) / Ann Neurol by SM Solano (2000)
  70. Kasap M, Akpinar G, Sazci A, Idrisoglu HA, Vahaboglu H (2009) Evidence for the presence of full-length PARK2 mRNA and parkin protein in human blood. Neurosci Lett 460(3):196–200. doi: 10.1016/j.neulet.2009.05.079 (10.1016/j.neulet.2009.05.079) / Neurosci Lett by M Kasap (2009)
  71. Pawlyk AC, Giasson BI, Sampathu DM, Perez FA, Lim KL, Dawson VL, Dawson TM, Palmiter RD, Trojanowski JQ, Lee VM (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 278(48):48120–48128. doi: 10.1074/jbc.M306889200 (10.1074/jbc.M306889200) / J Biol Chem by AC Pawlyk (2003)
  72. Horowitz JM, Myers J, Stachowiak MK, Torres G (1999) Identification and distribution of Parkin in rat brain. Neuroreport 10(16):3393–3397 (10.1097/00001756-199911080-00025) / Neuroreport by JM Horowitz (1999)
  73. Stichel CC, Augustin M, Kuhn K, Zhu XR, Engels P, Ullmer C, Lubbert H (2000) Parkin expression in the adult mouse brain. Eur J Neurosci 12(12):4181–4194 (10.1111/j.1460-9568.2000.01314.x) / Eur J Neurosci by CC Stichel (2000)
  74. Gu WJ, Abbas N, Lagunes MZ, Parent A, Pradier L, Bohme GA, Agid Y, Hirsch EC, Raisman-Vozari R, Brice A (2000) Cloning of rat parkin cDNA and distribution of parkin in rat brain. J Neurochem 74(4):1773–1776 (10.1046/j.1471-4159.2000.0741773.x) / J Neurochem by WJ Gu (2000)
  75. Huynh DP, Dy M, Nguyen D, Kiehl TR, Pulst SM (2001) Differential expression and tissue distribution of parkin isoforms during mouse development. Brain Res Dev Brain Res 130(2):173–181 (10.1016/S0165-3806(01)00234-6) / Brain Res Dev Brain Res by DP Huynh (2001)
  76. D’Agata V, Grimaldi M, Pascale A, Cavallaro S (2000) Regional and cellular expression of the parkin gene in the rat cerebral cortex. Eur J Neurosci 12(10):3583–3588 (10.1046/j.1460-9568.2000.00244.x) / Eur J Neurosci by V D’Agata (2000)
  77. Pogson JH, Ivatt RM, Whitworth AJ (2011) Molecular mechanisms of PINK1-related neurodegeneration. Curr Neurol Neurosci Rep 11(3):283–290. doi: 10.1007/s11910-011-0187-x (10.1007/s11910-011-0187-x) / Curr Neurol Neurosci Rep by JH Pogson (2011)
  78. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780. doi: 10.1002/humu.21277 (10.1002/humu.21277) / Hum Mutat by K Nuytemans (2010)
  79. Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, Goldwurm S, Valente EM (2007) Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum Mutat 28(1):98. doi: 10.1002/humu.9472 (10.1002/humu.9472) / Hum Mutat by R Marongiu (2007)
  80. Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J, Pastor P (2010) PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133(Pt 4):1128–1142. doi: 10.1093/brain/awq051 (10.1093/brain/awq051) / Brain by L Samaranch (2010)
  81. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160. doi: 10.1126/science.1096284 (10.1126/science.1096284) / Science by EM Valente (2004)
  82. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14(22):3477–3492. doi: 10.1093/hmg/ddi377 (10.1093/hmg/ddi377) / Hum Mol Genet by L Silvestri (2005)
  83. Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 102(16):5703–5708. doi: 10.1073/pnas.0500617102 (10.1073/pnas.0500617102) / Proc Natl Acad Sci U S A by A Beilina (2005)
  84. d’Amora M, Angelini C, Marcoli M, Cervetto C, Kitada T, Vallarino M (2011) Expression of PINK1 in the brain, eye and ear of mouse during embryonic development. J Chem Neuroanat 41(2):73–85. doi: 10.1016/j.jchemneu.2010.11.004 (10.1016/j.jchemneu.2010.11.004) / J Chem Neuroanat by M d’Amora (2011)
  85. Lin W, Kang UJ (2008) Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 106(1):464–474. doi: 10.1111/j.1471-4159.2008.05398.x (10.1111/j.1471-4159.2008.05398.x) / J Neurochem by W Lin (2008)
  86. Deas E, Plun-Favreau H, Gandhi S, Desmond H, Kjaer S, Loh SH, Renton AE, Harvey RJ, Whitworth AJ, Martins LM, Abramov AY, Wood NW (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum Mol Genet 20(5):867–879. doi: 10.1093/hmg/ddq526 (10.1093/hmg/ddq526) / Hum Mol Genet by E Deas (2011)
  87. Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, Mash DC, Farrer MJ (2004) DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 41(3):e22 (10.1136/jmg.2003.011106) / J Med Genet by PJ Lockhart (2004)
  88. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87. doi: 10.1146/annurev.neuro.28.061604.135718 (10.1146/annurev.neuro.28.061604.135718) / Annu Rev Neurosci by DJ Moore (2005)
  89. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, Heutink P (2003) DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24(3):159–160. doi: 10.1007/s10072-003-0108-0 (10.1007/s10072-003-0108-0) / Neurol Sci by V Bonifati (2003)
  90. van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69(3):629–634. doi: 10.1086/322996 (10.1086/322996) / Am J Hum Genet by CM Duijn van (2001)
  91. Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 91(4):1161–1218. doi: 10.1152/physrev.00022.2010 (10.1152/physrev.00022.2010) / Physiol Rev by O Corti (2011)
  92. Tarantino P, Civitelli D, Annesi F, De Marco EV, Rocca FE, Pugliese P, Nicoletti G, Carrideo S, Provenzano G, Annesi G, Quattrone A (2009) Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. Parkinsonism Relat Disord 15(4):324–326. doi: 10.1016/j.parkreldis.2008.07.001 (10.1016/j.parkreldis.2008.07.001) / Parkinsonism Relat Disord by P Tarantino (2009)
  93. Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, Hilker R, Vieregge P, Ozelius LJ, Heutink P, Bonifati V, Schwinger E, Lang AE, Noth J, Bressman SB, Pramstaller PP, Riess O, Klein C (2004) DJ-1 (PARK7) mutations are less frequent than parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62(3):389–394 (10.1212/01.WNL.0000113022.51739.88) / Neurology by K Hedrich (2004)
  94. Lev N, Roncevic D, Ickowicz D, Melamed E, Offen D (2006) Role of DJ-1 in Parkinson’s disease. J Mol Neurosci 29(3):215–225 (10.1385/JMN:29:3:215) / J Mol Neurosci by N Lev (2006)
  95. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM (2013) Neuroprotective function of DJ-1 in Parkinson’s disease. Oxid Med Cell Longev 2013:683920. doi: 10.1155/2013/683920 (10.1155/2013/683920) / Oxid Med Cell Longev by H Ariga (2013)
  96. Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA (2005) The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14(9):1231–1241. doi: 10.1093/hmg/ddi134 (10.1093/hmg/ddi134) / Hum Mol Genet by J Xu (2005)
  97. Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, McLendon C, Strand C, Leonard AJ, Abou-Sleiman PM, Healy DG, Ariga H, Wood NW, de Silva R, Revesz T, Hardy JA, Lees AJ (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 127(Pt 2):420–430. doi: 10.1093/brain/awh054 (10.1093/brain/awh054) / Brain by R Bandopadhyay (2004)
  98. Besong Agbo D, Klafki H, Poschmann G, Seyfarth K, Genius J, Janssen C, Stuhler K, Wurst W, Meyer HE, Klingenspor M, Wiltfang J (2013) Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples. Anal Biochem 443(2):197–204. doi: 10.1016/j.ab.2013.09.013 (10.1016/j.ab.2013.09.013) / Anal Biochem by D Besong Agbo (2013)
  99. Kumaran R, Kingsbury A, Coulter I, Lashley T, Williams D, de Silva R, Mann D, Revesz T, Lees A, Bandopadhyay R (2007) DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiol Dis 28(1):122–132. doi: 10.1016/j.nbd.2007.07.012 (10.1016/j.nbd.2007.07.012) / Neurobiol Dis by R Kumaran (2007)
  100. Kumaran R, Vandrovcova J, Luk C, Sharma S, Renton A, Wood NW, Hardy JA, Lees AJ, Bandopadhyay R (2009) Differential DJ-1 gene expression in Parkinson’s disease. Neurobiol Dis 36(2):393–400. doi: 10.1016/j.nbd.2009.08.011 (10.1016/j.nbd.2009.08.011) / Neurobiol Dis by R Kumaran (2009)
  101. Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J (2012) DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2:954. doi: 10.1038/srep00954 (10.1038/srep00954) / Sci Rep by X Lin (2012)
  102. Zhong N, Kim CY, Rizzu P, Geula C, Porter DR, Pothos EN, Squitieri F, Heutink P, Xu J (2006) DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem 281(30):20940–20948. doi: 10.1074/jbc.M601935200 (10.1074/jbc.M601935200) / J Biol Chem by N Zhong (2006)
  103. Vilarino-Guell C, Soto AI, Lincoln SJ, Ben Yahmed S, Kefi M, Heckman MG, Hulihan MM, Chai H, Diehl NN, Amouri R, Rajput A, Mash DC, Dickson DW, Middleton LT, Gibson RA, Hentati F, Farrer MJ (2009) ATP13A2 variability in Parkinson disease. Hum Mutat 30(3):406–410. doi: 10.1002/humu.20877 (10.1002/humu.20877) / Hum Mutat by C Vilarino-Guell (2009)
  104. Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1(1):11. doi: 10.1186/2051-5960-1-11 (10.1186/2051-5960-1-11) / Acta Neuropathol Commun by KE Murphy (2013)
  105. Ugolino J, Fang S, Kubisch C, Monteiro MJ (2011) Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum Mol Genet 20(18):3565–3577. doi: 10.1093/hmg/ddr274 (10.1093/hmg/ddr274) / Hum Mol Genet by J Ugolino (2011)
  106. Lu CS, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, Chang HC, Wu-Chou YH, Yeh TH (2012) PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 159B(2):183–191. doi: 10.1002/ajmg.b.32012 (10.1002/ajmg.b.32012) / Am J Med Genet B Neuropsychiatr Genet by CS Lu (2012)
  107. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V (2009) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72(3):240–245. doi: 10.1212/01.wnl.0000338144.10967.2b (10.1212/01.wnl.0000338144.10967.2b) / Neurology by A Fonzo Di (2009)
  108. Deng H, Liang H, Jankovic J (2013) F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol 70(1):20–24. doi: 10.1001/jamaneurol.2013.572 (10.1001/jamaneurol.2013.572) / JAMA Neurol by H Deng (2013)
  109. Gomez-Garre P, Jesus S, Carrillo F, Caceres-Redondo MT, Huertas-Fernandez I, Bernal-Bernal I, Bonilla-Toribio M, Vargas-Gonzalez L, Carballo M, Mir P (2014) Systematic mutational analysis of FBXO7 in a Parkinson’s disease population from southern Spain. Neurobiol Aging 35(3):727. e5–7. doi: 10.1016/j.neurobiolaging.2013.09.011 (10.1016/j.neurobiolaging.2013.09.011)
  110. Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C (2000) cDNA cloning and expression analysis of new members of the mammalian F-box protein family. Genomics 67(1):40–47. doi: 10.1006/geno.2000.6211 (10.1006/geno.2000.6211) / Genomics by GP Ilyin (2000)
  111. Zhao T, De Graaff E, Breedveld GJ, Loda A, Severijnen LA, Wouters CH, Verheijen FW, Dekker MC, Montagna P, Willemsen R, Oostra BA, Bonifati V (2011) Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS ONE 6(2):e16983. doi: 10.1371/journal.pone.0016983 (10.1371/journal.pone.0016983) / PLoS ONE by T Zhao (2011)
  112. Nolte D, Niemann S, Muller U (2003) Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A 100(18):10347–10352. doi: 10.1073/pnas.1831949100 (10.1073/pnas.1831949100) / Proc Natl Acad Sci U S A by D Nolte (2003)
  113. Herzfeld T, Nolte D, Grznarova M, Hofmann A, Schultze JL, Muller U (2013) X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism. Hum Mol Genet 22(5):941–951. doi: 10.1093/hmg/dds499 (10.1093/hmg/dds499) / Hum Mol Genet by T Herzfeld (2013)
  114. Korvatska O, Strand NS, Berndt JD, Strovas T, Chen DH, Leverenz JB, Kiianitsa K, Mata IF, Karakoc E, Greenup JL, Bonkowski E, Chuang J, Moon RT, Eichler EE, Nickerson DA, Zabetian CP, Kraemer BC, Bird TD, Raskind WH (2013) Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet 22(16):3259–3268. doi: 10.1093/hmg/ddt180 (10.1093/hmg/ddt180) / Hum Mol Genet by O Korvatska (2013)
  115. Myhre R, Klungland H, Farrer MJ, Aasly JO (2008) Genetic association study of synphilin-1 in idiopathic Parkinson’s disease. BMC Med Genet 9:19. doi: 10.1186/1471-2350-9-19 (10.1186/1471-2350-9-19) / BMC Med Genet by R Myhre (2008)
  116. Keyser RJ, Oppon E, Carr JA, Bardien S (2011) Identification of Parkinson’s disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson’s disease patients. J Neural Transm 118(6):889–897. doi: 10.1007/s00702-011-0591-z (10.1007/s00702-011-0591-z) / J Neural Transm by RJ Keyser (2011)
  117. Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schols L, Schulz JB, Riess O, Kruger R (2003) Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet 12(11):1223–1231 (10.1093/hmg/ddg134) / Hum Mol Genet by FP Marx (2003)
  118. Eyal A, Szargel R, Avraham E, Liani E, Haskin J, Rott R, Engelender S (2006) Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc Natl Acad Sci U S A 103(15):5917–5922. doi: 10.1073/pnas.0509707103 (10.1073/pnas.0509707103) / Proc Natl Acad Sci U S A by A Eyal (2006)
  119. Eyal A, Engelender S (2006) Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson’s disease. Cell Cycle 5(18):2082–2086 (10.4161/cc.5.18.3209) / Cell Cycle by A Eyal (2006)
  120. Szargel R, Rott R, Engelender S (2008) Synphilin-1 isoforms in Parkinson’s disease: regulation by phosphorylation and ubiquitylation. Cell Mol Life Sci 65(1):80–88. doi: 10.1007/s00018-007-7343-0 (10.1007/s00018-007-7343-0) / Cell Mol Life Sci by R Szargel (2008)
  121. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol 42(11):1775–1778. doi: 10.1016/j.biocel.2010.07.016 (10.1016/j.biocel.2010.07.016) / Int J Biochem Cell Biol by P Lei (2010)
  122. Spatola M, Wider C (2014) Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord 20(1):S35–S38. doi: 10.1016/S1353-8020(13)70011-7 (10.1016/S1353-8020(13)70011-7) / Parkinsonism Relat Disord by M Spatola (2014)
  123. Svobodova E, Mrazova L, Luksan O, Elstein D, Zimran A, Stolnaya L, Minks J, Eberova J, Dvorakova L, Jirsa M, Hrebicek M (2011) Glucocerebrosidase gene has an alternative upstream promoter, which has features and expression characteristic of housekeeping genes. Blood Cells Mol Dis 46(3):239–245. doi: 10.1016/j.bcmd.2010.12.011 (10.1016/j.bcmd.2010.12.011) / Blood Cells Mol Dis by E Svobodova (2011)
  124. Jakubauskiene E, Janaviciute V, Peciuliene I, Soderkvist P, Kanopka A (2012) G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease. FEBS Lett 586(20):3698–3704. doi: 10.1016/j.febslet.2012.08.028 (10.1016/j.febslet.2012.08.028) / FEBS Lett by E Jakubauskiene (2012)
  125. Thomas T (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol Aging 21(2):343–348 (10.1016/S0197-4580(00)00100-7) / Neurobiol Aging by T Thomas (2000)
  126. Stern G (1998) Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm Suppl 52:99–107 (10.1007/978-3-7091-6499-0_12) / J Neural Transm Suppl by G Stern (1998)
  127. Ho SL, Kapadi AL, Ramsden DB, Williams AC (1995) An allelic association study of monoamine oxidase B in Parkinson’s disease. Ann Neurol 37(3):403–405. doi: 10.1002/ana.410370318 (10.1002/ana.410370318) / Ann Neurol by SL Ho (1995)
  128. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson’s disease. Ann Neurol 33(4):368–372. doi: 10.1002/ana.410330406 (10.1002/ana.410330406) / Ann Neurol by JH Kurth (1993)
  129. Sobell JL, Lind TJ, Hebrink DD, Heston LL, Sommer SS (1997) Screening the monoamine oxidase B gene in 100 male patients with schizophrenia: a cluster of polymorphisms in African-Americans but lack of functionally significant sequence changes. Am J Med Genet 74(1):44–49 (10.1002/(SICI)1096-8628(19970221)74:1<44::AID-AJMG10>3.0.CO;2-R) / Am J Med Genet by JL Sobell (1997)
  130. Shehadeh LA, Yu K, Wang L, Guevara A, Singer C, Vance J, Papapetropoulos S (2010) SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson’s disease. PLoS ONE 5(2):e9104. doi: 10.1371/journal.pone.0009104 (10.1371/journal.pone.0009104) / PLoS ONE by LA Shehadeh (2010)
  131. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T (2008) Neuronal gene expression correlates of Parkinson’s disease with dementia. Mov Disord 23(11):1588–1595. doi: 10.1002/mds.22184 (10.1002/mds.22184) / Mov Disord by C Stamper (2008)
  132. Soreq L, Bergman H, Israel Z, Soreq H (2012) Exon arrays reveal alternative splicing aberrations in Parkinson’s disease leukocytes. Neurodegener Dis 10(1–4):203–206. doi: 10.1159/000332598 (10.1159/000332598) / Neurodegener Dis by L Soreq (2012)
  133. Soreq L, Bergman H, Israel Z, Soreq H (2013) Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson’s patients leukocytes. BMC Genomics 14:478. doi: 10.1186/1471-2164-14-478 (10.1186/1471-2164-14-478) / BMC Genomics by L Soreq (2013)
  134. Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA (2012) Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients. PLoS ONE 7(8):e43595. doi: 10.1371/journal.pone.0043595 (10.1371/journal.pone.0043595) / PLoS ONE by JA Potashkin (2012)
  135. Santiago JA, Scherzer CR, Harvard Biomarker S, Potashkin JA (2013) Specific splice variants are associated with Parkinson’s disease. Mov Disord 28(12):1724–1727. doi: 10.1002/mds.25635 (10.1002/mds.25635) / Mov Disord by JA Santiago (2013)
  136. Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, Soreq H (2014) Long non-coding RNA and alternative splicing modulations in Parkinson’s leukocytes identified by RNA sequencing. PLoS Comput Biol 10(3):e1003517. doi: 10.1371/journal.pcbi.1003517 (10.1371/journal.pcbi.1003517) / PLoS Comput Biol by L Soreq (2014)
  137. Soreq L, Salomonis N, Bronstein M, Greenberg DS, Israel Z, Bergman H, Soreq H (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci 6:10. doi: 10.3389/fnmol.2013.00010 (10.3389/fnmol.2013.00010) / Front Mol Neurosci by L Soreq (2013)
Dates
Type When
Created 10 years, 3 months ago (May 14, 2015, 11:23 p.m.)
Deposited 1 year, 2 months ago (June 8, 2024, 8:13 p.m.)
Indexed 1 week, 2 days ago (Aug. 19, 2025, 6:18 a.m.)
Issued 10 years, 3 months ago (May 16, 2015)
Published 10 years, 3 months ago (May 16, 2015)
Published Online 10 years, 3 months ago (May 16, 2015)
Published Print 9 years, 10 months ago (Oct. 1, 2015)
Funders 0

None

@article{La_Cognata_2015, title={Splicing: is there an alternative contribution to Parkinson’s disease?}, volume={16}, ISSN={1364-6753}, url={http://dx.doi.org/10.1007/s10048-015-0449-x}, DOI={10.1007/s10048-015-0449-x}, number={4}, journal={neurogenetics}, publisher={Springer Science and Business Media LLC}, author={La Cognata, Valentina and D’Agata, Velia and Cavalcanti, Francesca and Cavallaro, Sebastiano}, year={2015}, month=may, pages={245–263} }